134 related articles for article (PubMed ID: 21193869)
1. The relevance of assessment of intestinal P-gp inhibition using digoxin as an in vivo probe substrate.
Shi JG; Zhang Y; Yeleswaram S
Nat Rev Drug Discov; 2011 Jan; 10(1):75; author reply 75. PubMed ID: 21193869
[No Abstract] [Full Text] [Related]
2. Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P-gp Inhibition.
Chu X; Galetin A; Zamek-Gliszczynski MJ; Zhang L; Tweedie DJ;
Clin Pharmacol Ther; 2018 Nov; 104(5):788-792. PubMed ID: 30238965
[No Abstract] [Full Text] [Related]
3. Montmorillonite-surfactant hybrid particles for modulating intestinal P-glycoprotein-mediated transport.
Nielsen RB; Kahnt A; Dillen L; Wuyts K; Snoeys J; Nielsen UG; Holm R; Nielsen CU
Int J Pharm; 2019 Nov; 571():118696. PubMed ID: 31525443
[TBL] [Abstract][Full Text] [Related]
4. Fructose-induced metabolic syndrome decreases protein expression and activity of intestinal P-glycoprotein.
Novak A; Godoy YC; Martinez SA; Ghanem CI; Celuch SM
Nutrition; 2015 Jun; 31(6):871-6. PubMed ID: 25933496
[TBL] [Abstract][Full Text] [Related]
5. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats.
Zhang H; Yao M; Morrison RA; Chong S
Arch Pharm Res; 2003 Sep; 26(9):768-72. PubMed ID: 14560928
[TBL] [Abstract][Full Text] [Related]
6. Loxapine P-glycoprotein interactions in vitro.
Reed A; Huie K; Perloff ES; Cassella JV; Takahashi LH
Drug Metab Lett; 2012 Mar; 6(1):26-32. PubMed ID: 22300294
[TBL] [Abstract][Full Text] [Related]
7. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Liu PQ; Duan W; Chowbay B; Wen JY; Li CG; Zhou SF
Curr Drug Metab; 2007 May; 8(4):325-40. PubMed ID: 17504222
[TBL] [Abstract][Full Text] [Related]
8. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells.
Zhang S; Morris ME
Pharm Res; 2003 Aug; 20(8):1184-91. PubMed ID: 12948016
[TBL] [Abstract][Full Text] [Related]
9. Digestion of surfactants does not affect their ability to inhibit P-gp-mediated transport in vitro.
Rasmussen AJ; Pedersen M; Griffin BT; Holm R; Nielsen CU
Int J Pharm; 2024 May; 656():124120. PubMed ID: 38621613
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo and in vivo investigations of the effects of extracts of Vernonia amygdalina, Carica papaya and Tapinanthus sessilifolius on digoxin transport and pharmacokinetics: assessing the significance on rat intestinal P-glycoprotein efflux.
Oga EF; Sekine S; Horie T
Drug Metab Pharmacokinet; 2013; 28(4):314-20. PubMed ID: 23291634
[TBL] [Abstract][Full Text] [Related]
11. Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
Zhao Y; Hu ZY
Br J Pharmacol; 2014 Feb; 171(4):1043-53. PubMed ID: 24283665
[TBL] [Abstract][Full Text] [Related]
12. Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans.
Parker RB; Yates CR; Soberman JE; Laizure SC
Pharmacotherapy; 2003 Aug; 23(8):979-87. PubMed ID: 12921244
[TBL] [Abstract][Full Text] [Related]
13. Transport characteristics of tryptanthrin and its inhibitory effect on P-gp and MRP2 in Caco-2 cells.
Zhu X; Zhang X; Ma G; Yan J; Wang H; Yang Q
J Pharm Pharm Sci; 2011; 14(3):325-35. PubMed ID: 21824448
[TBL] [Abstract][Full Text] [Related]
14. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.
Tachibana T; Kato M; Takano J; Sugiyama Y
Curr Drug Metab; 2010 Nov; 11(9):762-77. PubMed ID: 21189139
[TBL] [Abstract][Full Text] [Related]
15. Effects of Acanthopanax senticosus HARMS extract on drug transport in human intestinal cell line Caco-2.
Takahashi T; Kaku T; Sato T; Watanabe K; Sato J
J Nat Med; 2010 Jan; 64(1):55-62. PubMed ID: 20091240
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics.
Hughes J; Crowe A
J Pharmacol Sci; 2010; 113(4):315-24. PubMed ID: 20724802
[TBL] [Abstract][Full Text] [Related]
17. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.
Dahan A; Sabit H; Amidon GL
AAPS J; 2009 Jun; 11(2):205-13. PubMed ID: 19319690
[TBL] [Abstract][Full Text] [Related]
18. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells.
Cavet ME; West M; Simmons NL
Br J Pharmacol; 1996 Jul; 118(6):1389-96. PubMed ID: 8832062
[TBL] [Abstract][Full Text] [Related]
19. Quantitative prediction of P-glycoprotein-mediated drug-drug interactions and intestinal absorption using humanized mice.
Miyake T; Tsutsui H; Haraya K; Tachibana T; Morimoto K; Takehara S; Ayabe M; Kobayashi K; Kazuki Y
Br J Pharmacol; 2021 Nov; 178(21):4335-4351. PubMed ID: 34232502
[TBL] [Abstract][Full Text] [Related]
20. Regional difference in P-glycoprotein function in rat intestine.
Iida A; Tomita M; Hayashi M
Drug Metab Pharmacokinet; 2005 Apr; 20(2):100-6. PubMed ID: 15855720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
